At a glance
Type
GHRH analog · mod GRF(1-29)
Molecular weight
≈3367 g/mol (reported)
Half-life
~30 min (No DAC)
Studied for
Endogenous GHPairs with ipamorelinIGF-1 support
CJC-1295 (No DAC), also known as modified GRF(1-29), is a growth hormone–releasing hormone (GHRH) analog. It is a stabilised version of the first 29 residues of GHRH, engineered to resist the enzymes that quickly break down natural GHRH — prompting the pituitary to release the body’s own growth hormone. It is most often paired with a ghrelin-receptor agonist such as ipamorelin.
How CJC-1295 works
CJC-1295 binds the GHRH receptor on the pituitary and stimulates a pulse of the body’s own growth hormone, which in turn raises IGF-1. The “No DAC” form used here lacks the drug-affinity-complex group of the longer-acting version, so it has a short half-life (about 30 minutes) and produces a brief, natural-style GH pulse. That short action is exactly why it is commonly combined with ipamorelin, which triggers GH release through a complementary pathway.
What the research shows
- Prolonged GH/IGF-1 (Teichman et al., 2006). A single dose of the long-acting CJC-1295 (with DAC) raised GH 2–10× and IGF-1 1.5–3× for up to ~6–11 days in healthy adults.
- Pulsatility preserved (Ionescu & Frohman, 2006). Continuous CJC-1295 stimulation raised GH levels while preserving the natural pulsatile rhythm of secretion.
- Restored growth in models (Alba et al., 2006). Once-daily CJC-1295 normalised growth and raised IGF-1 in GHRH-deficient mice.
Candour on the evidence: the human data above come mainly from the longer-acting DAC version; the No-DAC / modified GRF(1-29) form specifically has little dedicated human-trial data, and long-term safety and efficacy are not established. Some molecular figures for the No-DAC form are supplier-reported rather than from primary literature. Use belongs under a physician’s guidance.
Molecular specification
| Type | GHRH analog · modified GRF(1-29), No DAC |
| Sequence | 30-amino-acid stabilised GRF(1-29) analog |
| Molecular formula | C152H252N44O42 (supplier-reported) |
| Molecular weight | ≈3367 g/mol (supplier-reported) |
| Half-life | ~30 min (No-DAC form) |
Quality and sourcing
Every batch of Azzurri Wellness CJC-1295 is compounded through a Registered 503B outsourcing facility under GMP-compliant processes, HPLC-tested for purity and potency, and third-party lab verified. Shipped cold-pack when needed to protect stability.
References
- Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. PubMed
- Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006;91(12):4792–4797. PubMed
- Alba M, et al. Once-daily CJC-1295 normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290–E1294. PubMed
Compiled by the Azzurri Wellness Research Team and checked against the cited literature. Educational only — not medical advice.
